Literature DB >> 28012615

ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2016 Appropriate Use Criteria for Coronary Revascularization in Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society of Thoracic Surgeons.

Manesh R Patel, John H Calhoon, Gregory J Dehmer, James Aaron Grantham, Thomas M Maddox, David J Maron, Peter K Smith.   

Abstract

The American College of Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, and American Association for Thoracic Surgery, along with key specialty and subspecialty societies, have completed a 2-part revision of the appropriate use criteria (AUC) for coronary revascularization. In prior coronary revascularization AUC documents, indications for revascularization in acute coronary syndromes (ACS) and stable ischemic heart disease were combined into 1 document. To address the expanding clinical indications for coronary revascularization, and in an effort to align the subject matter with the most current American College of Cardiology/American Heart Association guidelines, the new AUC for coronary artery revascularization were separated into 2 documents addressing ACS and stable ischemic heart disease individually. This document presents the AUC for ACS. Clinical scenarios were developed to mimic patient presentations encountered in everyday practice and included information on symptom status, presence of clinical instability or ongoing ischemic symptoms, prior reperfusion therapy, risk level as assessed by noninvasive testing, fractional flow reserve testing, and coronary anatomy. This update provides a reassessment of clinical scenarios that the writing group felt to be affected by significant changes in the medical literature or gaps from prior criteria. The methodology used in this update is similar to the initial document but employs the recent modifications in the methods for developing AUC, most notably, alterations in the nomenclature for appropriate use categorization. A separate, independent rating panel scored the clinical scenarios on a scale of 1 to 9. Scores of 7 to 9 indicate that revascularization is considered appropriate for the clinical scenario presented. Scores of 1 to 3 indicate that revascularization is considered rarely appropriate for the clinical scenario, whereas scores in the mid-range (4 to 6) indicate that coronary revascularization may be appropriate for the clinical scenario. Seventeen clinical scenarios were developed by a writing committee and scored by the rating panel: 10 were identified as appropriate, 6 as may be appropriate, and 1 as rarely appropriate. As seen with the prior coronary revascularization AUC, revascularization in clinical scenarios with ST-segment elevation myocardial infarction and non–ST-segment elevation myocardial infarction were considered appropriate. Likewise, clinical scenarios with unstable angina and intermediate- or high-risk features were deemed appropriate. Additionally, the management of nonculprit artery disease and the timing of revascularization are now also rated. The primary objective of the AUC is to provide a framework for the assessment of practice patterns that will hopefully improve physician decision making.

Entities:  

Keywords:  ACC Appropriate Use Criteria; coronary revascularization; imaging; medical therapy; multimodality

Mesh:

Year:  2016        PMID: 28012615     DOI: 10.1016/j.jacc.2016.10.034

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  36 in total

1.  Impact of two formulas to calculate percentage diameter stenosis of coronary lesions: from stenosis models (phantom lesion model) to actual clinical lesions.

Authors:  Alexandre Hideo-Kajita; Samuel Wopperer; Solomon S Beyene; Yael F Meirovich; Gebremedhin D Melaku; Kayode O Kuku; Echo J Brathwaite; Yuichi Ozaki; Kazuhiro Dan; Rebecca Torguson; Ron Waksman; Hector M Garcia-Garcia
Journal:  Int J Cardiovasc Imaging       Date:  2019-07-27       Impact factor: 2.357

2.  Comparison of ESC and ACC/AHA guidelines for myocardial revascularization: are the differences clinically relevant? The European perspective.

Authors:  Mario Petretta; Alberto Cuocolo
Journal:  J Nucl Cardiol       Date:  2017-04-21       Impact factor: 5.952

Review 3.  Guidelines in review: 2016 ACC/AATS/AHA/ASNC/SCAI/SCCT/STS appropriate use criteria for coronary revascularization in patients with acute coronary syndromes.

Authors:  Samuel K McElwee; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2017-01-31       Impact factor: 5.952

4.  [Percutaneous coronary interventions in infarct-related shock and multivessel disease : Only treat the infarct-related vessel or treat all relevant coronary stenoses?]

Authors:  U Janssens
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-11-16       Impact factor: 0.840

Review 5.  Complete versus culprit only revascularization in ST-elevation myocardial infarction-a perspective on recent trials and recommendations.

Authors:  Gabriela Andries; Sahil Khera; Robert J Timmermans; Wilbert S Aronow
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

6.  Extended antithrombotic therapy for secondary prevention of cardiovascular events: A tool for pharmacists.

Authors:  Kari Rustad; Kirsten Tangedal; Samantha Tri; William Semchuk
Journal:  Can Pharm J (Ott)       Date:  2021-09-21

7.  Association of High-Sensitivity Troponin with Cardiac CT Angiography Evidence of Myocardial and Coronary Disease in a Primary Prevention Cohort of Men: Results from MACS.

Authors:  Faisal Rahman; Zhenyu Zhang; Di Zhao; Matthew J Budoff; Frank J Palella; Mallory D Witt; Rhobert W Evans; Lisa P Jacobson; Frederick K Korley; Eliseo Guallar; Wendy S Post; John W McEvoy
Journal:  J Appl Lab Med       Date:  2019-04-23

Review 8.  Management of ST-Elevation Myocardial Infarction in High-Risk Settings.

Authors:  Mohamed A Omer; Jose E Exaire; Jacob C Jentzer; Yader B Sandoval; Mandeep Singh; Charles R Cagin; Islam Y Elgendy; Tahir Tak
Journal:  Int J Angiol       Date:  2021-02-12

9.  Multivessel versus Culprit-Only Revascularization Strategies in Cardiac Arrest Survivors.

Authors:  Wei-Ting Chen; Min-Shan Tsai; Chien-Hua Huang; Chih-Wei Sung; Po-Ya Chuang; Chih-Hung Wang; Yen-Wen Wu; Wei-Tien Chang; Wen-Jone Chen
Journal:  Acta Cardiol Sin       Date:  2022-03       Impact factor: 2.672

10.  Silent Myocardial Infarction and Long-Term Risk of Frailty: The Atherosclerosis Risk in Communities Study.

Authors:  Fanghui Li; Dongze Li; Jing Yu; Yu Jia; Yi Liu; Yanmei Liu; Qinqin Wu; Xiaoyang Liao; Zhi Zeng; Zhi Wan; Rui Zeng
Journal:  Clin Interv Aging       Date:  2021-06-18       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.